The FDA has approved MenQuadfiTM Meningococcal (Groups A, C, Y, W; Sanofi Pasteur) Conjugate Vaccine for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in patients aged ≥2 years.
The FDA has approved an expanded indication for the gammaCore device to include prevention of migraine.
The FDA has accepted for Priority Review the Biologics License Application (BLA) for REGN-EB3 for the treatment of Ebola virus infection.
The guide includes information on a drug’s origin, common street names, how it is abused, what effect it has on the mind and body, what the overdose effects are, and what its legal status is in the US.
The Agency believes that the ability to manage the cytokine storm associated with COVID-19 may decrease patient morbidity.
Data that informed these label changes came from research funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
The FDA has issued emergency use authorization for two point-of-care diagnostics for the qualitative detection of SARS-CoV-2, the virus causing coronavirus disease 2019 (COVID-19).
The Food and Drug Administration (FDA) has approved Nurtec™ ODT (rimegepant; Biohaven) for the acute treatment of migraine with or without aura in adults.
Symtuza is a 4-drug combination of darunavir, an HIV-1 protease inhibitor; cobicistat, a CYP3A inhibitor; and emtricitabine and tenofovir alafenamide.
Monoferric will be supplied in 100mg/mL, 500mg/5mL, and 1000mg/10mL single-dose vials for intravenous infusion after dilution.
